Bulletin
Investor Alert

New York Markets Open in:

Deciphera Pharmaceuticals Inc.

NAS: DCPH

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

Oct 15, 2021, 7:12 p.m.

/zigman2/quotes/203556943/composite

$

35.00

Change

+0.17 +0.49%

Volume

Volume 7,972

Quotes are delayed by 20 min

/zigman2/quotes/203556943/composite

Previous close

$ 34.69

$ 34.83

Change

+0.14 +0.40%

Day low

Day high

$34.12

$35.70

Open

52 week low

52 week high

$26.20

$68.40

Open

Daniel L. Flynn

Daniel L. Flynn founded Deciphera Pharmaceuticals, Inc. and Deciphera Pharmaceuticals LLC. Presently, Dr. Flynn occupies the position of Chief Scientific Officer & Executive VP at Deciphera Pharmaceuticals, Inc. and Director & Chief Scientific Officer at Deciphera Pharmaceuticals LLC (a subsidiary of Deciphera Pharmaceuticals, Inc.). He is also on the board of University of Kansas Center for Research, Inc.

In his past career he held the position of Director-Medicinal Chemistry at Amgen, Inc., Principal at Warner-Lambert Co., Senior Director-Chemistry at Millennium Pharmaceuticals, Inc., Director-Medicinal Chemistry at Monsanto Co., Principal at G.D. Searle & Co., Inc., Principal at Parke-Davis Pharmaceutical Research, Inc. and Chairman-Medicinal Chemistry Division at American Chemical Society.

Daniel L. Flynn received a doctorate and an undergraduate degree from the University of Kansas.

Transactions

Date Shares Transaction Value
02/16/2021 11,100   Award at $0 per share. 0
02/16/2021 508   Disposition at $48.87 per share. 24,826
08/10/2020 9,029   Derivative/Non-derivative trans. at $1.89 per share. 17,064
07/22/2020 130,000   Derivative/Non-derivative trans. at $1.89 per share. 245,700
02/18/2020 7,040   Award at $0 per share. 0
01/16/2020 56,800   Derivative/Non-derivative trans. at $6.13 per share. 348,184
01/16/2020 10,106   Derivative/Non-derivative trans. at $3.95 per share. 39,918
12/12/2019 31,029   Disposition at $60 per share. 1,861,740
12/10/2019 93,930   Disposition at $55 per share. 5,166,150
12/10/2019 93,930   Derivative/Non-derivative trans. at $1.89 per share. 177,527
12/10/2019 28,822   Disposition at $55 per share. 1,585,210
12/10/2019 28,822   Derivative/Non-derivative trans. at $1.89 per share. 54,473
12/09/2019 30,175   Disposition at $55 per share. 1,659,625
12/09/2019 30,175   Derivative/Non-derivative trans. at $1.89 per share. 57,030
11/11/2019 143,185   Disposition at $48.01 per share. 6,874,312
11/11/2019 143,185   Derivative/Non-derivative trans. at $1.89 per share. 270,619
11/08/2019 9,742   Disposition at $48 per share. 467,616
11/08/2019 9,742   Derivative/Non-derivative trans. at $1.89 per share. 18,412
10/28/2019 29,820   Disposition at $40 per share. 1,192,800
10/28/2019 29,820   Derivative/Non-derivative trans. at $1.89 per share. 56,359
08/13/2019 25,000   Disposition at $42.9 per share. 1,072,500
08/13/2019 29,712   Disposition at $41.33 per share. 1,227,997
08/13/2019 93,395   Disposition at $40.26 per share. 3,760,083
08/13/2019 123,107   Derivative/Non-derivative trans. at $1.89 per share. 232,672
02/21/2019 24,500   Derivative/Non-derivative trans. at $3.95 per share. 96,775
01/16/2019 152,629   Disposition at $26 per share. 3,968,354
01/16/2019 152,629   Derivative/Non-derivative trans. at $1.89 per share. 288,468
01/11/2019 300   Disposition at $26 per share. 7,800
01/11/2019 300   Derivative/Non-derivative trans. at $1.89 per share. 567
03/23/2018 91,779   Gift at $0 per share. 0
03/23/2018 91,779   Gift at $0 per share. 0
10/02/2017 147,049   Derivative/Non-derivative trans. at $0 per share. 0
08/02/2017 55,270   Gift at $0 per share. 0
08/02/2017 55,270   Gift at $0 per share. 0

Officers and Executives

Mr. Steven L. Hoerter
President, Chief Executive Officer & Director
Mr. Thomas P. Kelly
Chief Financial Officer, Treasurer & Executive VP
Dr. Matthew L. Sherman
Chief Medical Officer & Executive Vice President
Dr. Daniel L. Flynn
Chief Scientific Officer & Executive VP
Dr. Stephen B. Ruddy
Chief Technical Officer
Mr. Eric Haltom
Senior Vice President-Clinical Operations
Mr. Daniel C. Martin
Chief Commercial Officer
Ms. Jennifer Robinson
Head-Investor Relations
Ms. Caroline Chevalier
Vice President-Human Resources
Mr. Jeffrey M. Held
General Counsel & Senior Vice President
Mr. Jama Pitman
Vice President-Regulatory & Quality Assurance
Dr. James A. Bristol
Chairman
Dr. Susan L. Kelley
Independent Director
Mr. Ron Squarer
Independent Director
Mr. Franklin S. Friedman
Independent Director
Ms. Patricia L. Allen
Independent Director
Dr. Edward J. Benz
Independent Director
Mr. John R. Martin
Independent Director
Mr. Dennis L. Walsh
Independent Director
Link to MarketWatch's Slice.